IOVA
Iovance Biotherapeutics margins
- Stocks
- Healthcare
- NASDAQ: IOVA
- Margins
Iovance Biotherapeutics reports a gross margin of 48.4%, an operating margin of -92.7%, an EBITDA margin of -76.5%, and a net margin of -89.1%, but its operating margin is negative at -92.7%, its EBITDA margin is negative at -76.5%, and its net margin is negative at -89.1%. All available margins expanded year over year, led by operating margin with an increase of 77.3 percentage points.
IOVA margin history
Over the last 3 years, Iovance Biotherapeutics's margins averaged -4.03% gross, -6,026.99% operating, -5,396.65% EBITDA, and -5,803.69% net. All four current margins are above their three-year averages.
IOVA margin expansion
Gross margin expanded by 15 percentage points, operating margin by 77.3 percentage points, EBITDA margin by 64 percentage points, and net margin by 72.3 percentage points, led by operating margin with an increase of 77.3 percentage points.
IOVA Gross margin
Throughout the last 3 years, Iovance Biotherapeutics had an average gross margin of -4.03%. Against its three-year average, Iovance Biotherapeutics's gross margin is currently 48.4%, 52.4 percentage points above its three-year average. Looking back over the last 3 years, Iovance Biotherapeutics's gross margin reached 48.4% at its highest point in Jun 2026 and -335.6% at its lowest in Mar 2024.
IOVA Operating margin
Over the last 3 years, Iovance Biotherapeutics's operating margin averaged -6,026.99%. As of the latest period, Iovance Biotherapeutics's current operating margin is -92.7%, which is 5,934.3 percentage points above its three-year average. During this period, operating margin reached a high of -92.7% in Jun 2026 and a low of -38,735% in Dec 2023.
IOVA EBITDA margin
Iovance Biotherapeutics recorded an average EBITDA margin of -5,396.65% across the last 3 years. Iovance Biotherapeutics's current EBITDA margin is -76.5% and is 5,320.2 percentage points above its three-year average. The highest EBITDA margin for Iovance Biotherapeutics was -76.5% in Jun 2026, while the lowest was -34,851.9% in Dec 2023.
IOVA Net margin
Reviewing the last 3 years, Iovance Biotherapeutics recorded an average net margin of -5,803.69%. Iovance Biotherapeutics's current net margin is -89.1% and is 5,714.6 percentage points above its three-year average. The highest net margin for Iovance Biotherapeutics was -89.1% in Jun 2026, while the lowest was -37,345.4% in Dec 2023.
IOVA margin group comparison
Iovance Biotherapeutics's gross margin of 48.4% is lower than the Healthcare sector and the industry average. In comparison with the Healthcare sector average of 68.3%, Iovance Biotherapeutics's gross margin is 29% lower.
Frequently asked questions
What is Iovance Biotherapeutics's gross margin?
For the period ending Jun 30, 2026, IOVA recorded a gross margin of 48.4%.
What is Iovance Biotherapeutics's operating margin?
For the period ending Jun 30, 2026, IOVA recorded an operating margin of -92.7%.
What is Iovance Biotherapeutics's EBITDA margin?
As of Jun 30, 2026, IOVA has an EBITDA margin of -76.5%.
What is Iovance Biotherapeutics's net margin?
As of Jun 30, 2026, IOVA has a negative net margin of -89.1%.
What are the average margins of IOVA?
Iovance Biotherapeutics's gross, operating, EBITDA, and net margins averaged -4.0% gross, -6,027.0% operating, -5,396.7% EBITDA, and -5,803.7% net over the last 3 years.
What are the highest historical margins of IOVA?
Over this 5-year history, IOVA peaked at 48.4% gross in Jun 2026, -92.7% operating in Jun 2026, -76.5% EBITDA in Jun 2026, and -89.1% net in Jun 2026.
What are the lowest historical margins of IOVA?
Looking back across 5 years, IOVA reached its lowest margins at -803.8% gross in Sep 2023, -179,988.7% operating in Jun 2023, -165,909.7% EBITDA in Jun 2023, and -175,981.1% net in Jun 2023.